» Articles » PMID: 35432316

Computer-Based Immunoinformatic Analysis to Predict Candidate T-Cell Epitopes for SARS-CoV-2 Vaccine Design

Overview
Journal Front Immunol
Date 2022 Apr 18
PMID 35432316
Authors
Affiliations
Soon will be listed here.
Abstract

Since the first outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, its high infectivity led to its prevalence around the world in an exceptionally short time. Efforts have been made to control the ongoing outbreak, and among them, vaccine developments are going on high priority. New clinical trials add to growing evidence that vaccines from many countries were highly effective at preventing SARS-CoV-2 virus infection. One of them is B cell-based vaccines, which were common during a pandemic. However, neutralizing antibody therapy becomes less effective when viruses mutate. In order to tackle the problem, we focused on T-cell immune mechanism. In this study, the mutated strains of the virus were selected globally from India (B.1.617.1 and B.1.617.2), United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1), and the overlapping peptides were collected based on mutation sites of S-protein. After that, residue scanning was used to predict the affinity between overlapping peptide and HLA-A*11:01, the most frequent human leukocyte antigen (HLA) allele among the Chinese population. Then, the binding free energy was evaluated with molecular docking to further verify the affinity changes after the mutations happen in the virus genomes. The affinity test results of three epitopes on spike protein from experimental validation were consistent with our predicted results, thereby supporting the inclusion of the epitope FSTFKCYGL in future vaccine design and providing a useful reference route to improve vaccine development.

Citing Articles

CovEpiAb: a comprehensive database and analysis resource for immune epitopes and antibodies of human coronaviruses.

Zhang X, Wu J, Luo Y, Wang Y, Wu Y, Xu X Brief Bioinform. 2024; 25(3).

PMID: 38653491 PMC: 11036340. DOI: 10.1093/bib/bbae183.


Use of Immunoglobulin Y Antibodies: Biosensor-based Diagnostic Systems and Prophylactic and Therapeutic Drug Delivery Systems for Viral Respiratory Diseases.

Budama-Kilinc Y, Kurtur O, Gok B, Cakmakci N, Kecel-Gunduz S, Unel N Curr Top Med Chem. 2024; 24(11):973-985.

PMID: 38561616 DOI: 10.2174/0115680266289898240322073258.

References
1.
Singh H, Jakhar R, Sehrawat N . Designing spike protein (S-Protein) based multi-epitope peptide vaccine against SARS COVID-19 by immunoinformatics. Heliyon. 2020; 6(11):e05528. PMC: 7667438. DOI: 10.1016/j.heliyon.2020.e05528. View

2.
Fadaka A, Aruleba R, Sibuyi N, Klein A, Madiehe A, Meyer M . Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach. J Biomol Struct Dyn. 2020; 40(8):3416-3427. PMC: 7682381. DOI: 10.1080/07391102.2020.1847197. View

3.
Goletti D, Petrone L, Manissero D, Bertoletti A, Rao S, Ndunda N . The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. Clin Microbiol Infect. 2021; 27(12):1784-1789. PMC: 8272618. DOI: 10.1016/j.cmi.2021.07.005. View

4.
Lin H, Chen C, Chiao D, Chang T, Chen X, Young J . Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice. Int J Biol Macromol. 2021; 193(Pt B):1885-1897. PMC: 8580573. DOI: 10.1016/j.ijbiomac.2021.11.020. View

5.
ODonnell T, Rubinsteyn A, Laserson U . MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing. Cell Syst. 2020; 11(4):418-419. DOI: 10.1016/j.cels.2020.09.001. View